Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial - Top-Institutions - MDSpire

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial

  • By

  • Hao-Rui Shen

  • Jia-Zhu Wu

  • Hua Yin

  • Kai-Xin Du

  • Luthuli Sibusiso

  • Yi-Fan Wu

  • Wei Hua

  • Yue Li

  • Yi-Lin Kong

  • Xin-Yu Zhang

  • Rui Gao

  • Jian-Yong Li

  • Li Wang

  • Jin-Hua Liang

  • Wei Xu

  • February 11, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neuro-Oncology
    • Hematology
    • Immunotherapy

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Neuro-Oncology
    • Immunotherapy

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neuro-Oncology
    • Hematology
    • Clinical Trials

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Neuro-Oncology
    • Hematology
    • Immunotherapy

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Neuro-Oncology
    • Hematology
    • Immunotherapy

Original Source(s)

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial

  • by Hao-Rui Shen, Jia-Zhu Wu, Hua Yin, Kai-Xin Du, Luthuli Sibusiso, Yi-Fan Wu, Wei Hua, Yue Li, Yi-Lin Kong, Xin-Yu Zhang, Rui Gao, Jian-Yong Li, Li Wang, Jin-Hua Liang, Wei Xu

  • February 11, 2026

Related Content

Unravelling genomic differences in cerebrospinal fluid: patients with lung cancer with combined brain parenchymal and meningeal metastasis versus exclusive meningeal metastasis

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

Arterial spin labelling MRI for brain tumour surveillance: do we really need cerebral blood flow maps?